Compare PARK & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PARK | ACET |
|---|---|---|
| Founded | 1972 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.5M | 71.3M |
| IPO Year | 2025 | N/A |
| Metric | PARK | ACET |
|---|---|---|
| Price | $15.50 | $8.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $96.67 |
| AVG Volume (30 Days) | 57.9K | ★ 199.8K |
| Earning Date | 02-08-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.18 | N/A |
| EPS | ★ 2.91 | N/A |
| Revenue | ★ $240,209,000.00 | N/A |
| Revenue This Year | $7.62 | N/A |
| Revenue Next Year | $5.75 | N/A |
| P/E Ratio | $5.21 | ★ N/A |
| Revenue Growth | ★ 7.47 | N/A |
| 52 Week Low | $9.53 | $7.15 |
| 52 Week High | $17.84 | $17.44 |
| Indicator | PARK | ACET |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 79.68 |
| Support Level | N/A | $7.70 |
| Resistance Level | N/A | $8.56 |
| Average True Range (ATR) | 0.00 | 0.50 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 0.00 | 90.54 |
Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.